Key Specifications Table
Pricing & Availability
An invalid quantity was specified. The product quantity has been adjusted.
|219467-10UG||Plastic ampoule||10 μg||
|Overview||Recombinant, human procathepsin V (amino acids 18-334) fused at the N-terminus to a CD33 signal sequence (amino acids 1-16) and at the C-terminus to a His•Tag® sequence and expressed in NSO cells. Cat V is predominantly expressed in normal thymus, testis, and corneal epithelium. It is involved in the invariant chain degradation in thymic epithelial cells and its overexpression has been detected in myasthenia gravis. Abnormally wide spread expressions in mammary gland and colon have also been reported in breast and colonrectal carcinomas. Although it shows high amino acid identity with cathepsin L (Cat. No. 219382), these two cathepsins have very different tissue distribution and substrate specificity. As a result of glycosylation, this recombinant enzyme migrates ~40 kDa on SDS-PAGE under either reducing or non-reducing conditions. Requires activation prior to use.|
|Synonyms||Cathepsin L2, Cathepsin U|
|Purity||≥95% by SDS-PAGE|
|Specific Activity||≥300 units/µg|
|Concentration Label||Please refer to vial label for lot-specific concentration|
|Contaminants||Endotoxins: ≤1.0 EU/µg Cathepsin V|
|Safety Information according to GHS|
|Product Usage Statements|
Cathepsin V, His•Tag®, Human, Recombinant, NSO Cells SDS
|Tolosa, E., et al. 2003. J. Clin. Invest. 112, 517.
Turk, V., et al. 2001. EMBO J. 20, 4629.
Somoza, J.R., et al. 2000. Biochemistry 39, 12543.
Bromme, D., et al. 1999. Biochemistry 38, 2377.
Adachi, W., et al. 1998. Invest. Ophthalmol. Vis. Sci. 39, 1789.
Santamaria, I., et al. 1998. Cancer Res. 58, 1624.